NRSN

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

Patent Protection Through October 2042Follows prior patent grants in the U.S. and AustraliaFurther strengthens NeuroSense's global intellectual property portfolioCAMBRIDGE, Mass., April 6, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Brazilian Patent and Trademark Office (INPI) has granted Brazilian Patent No. BR 112024007727-6, entitled "Compositions Comprising Ciprofloxacin and Celecoxib."   The granted Brazilian patent, following prior approval of the corresponding U.S. patent (12,097,185) and Australian

Notifications have no immediate effect on the listing or trading of the Company's securities on NasdaqNasdaq has provided the Company until September 29, 2026 to regain compliance with both requirementsThe Company is actively evaluating actions to regain compliance, with a clear focus on initiatives that are aligned with and supportive of long-term shareholder valueCAMBRIDGE, Mass., April 3, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company developing treatments for severe neurodegenerative diseases, today announced that it received two notification letters from the Listing Qualifications Department of

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

4 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)

3 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)

3 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

20-F - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program in ALSStatistically significant survival benefit demonstrated, including 65% reduction in risk of death and >14-month median survival advantageResults published in JAMA Neurology, providing high-level peer-reviewed validation of clinical and biological activityAdvancing toward key regulatory milestones with planned pre-NDS meeting in Canada and near-term Alzheimer's readoutCAMBRIDGE, Mass., March 31, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company developing treatments for severe neurodegenerative disea

3 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)

4 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)

3 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)

4 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today provided an update on key regulatory and clinical milestones for its lead asset, PrimeC.   Health Canada Pre-NDS Meeting A pre-New Drug Submission (pre-NDS) meeting with Health Canada has been rescheduled to May 2026.The decision was made to allow for the inclusion of additional emerging clinical, biomarker and survival data and analyses in the briefing package, which the Company believes will meaningfully strengthen the scientific and clinical foundation

3 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)

3 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)

3 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)

3 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)

3 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)

3 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)

In the news release, PrimeC New Data to Be Presented at AD/PD™ 2026 Conference, issued 18-Mar-2026 by NeuroSense over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows: PrimeC New Data to Be Presented at AD/PD™ 2026 Conference Dr. Christian Lunetta to Present "From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2 Clinical and Biomarker Insights toward a Global Phase 3 Trial"CAMBRIDGE, Mass., March 18, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announ

Dr. Christian Lunetta to Present "From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2 Clinical and Biomarker Insights toward a Global Phase 3 Trial"CAMBRIDGE, Mass., March 18, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that Dr. Christian Lunetta will present new data and insights on the development of PrimeC, the company's investigational therapy for amyotrophic lateral sclerosis (ALS), at the AD/PD™ 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disord

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)